ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1796, Issue 2, 2009, Pages 162-175

  Chen, Jin Qiang ^a   Russo, Jose ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast cancer; CXC chemokine; CXCL8; ER ; ER ; Estrogen carcinogenesis; GRCP 30 EGFR; microRNAs; Therapeutic approaches for TN breast cancer; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CATECHOL ESTROGEN; CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPITHELIAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; MICRORNA; NOTCH RECEPTOR; OSTEOPONTIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SURVIVIN; UNCLASSIFIED DRUG; UVOMORULIN; ALPHA CHEMOKINE; CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN; PROGESTERONE RECEPTOR;

BREAST CANCER; CLINICAL FEATURE; ENZYME ACTIVATION; GENE EXPRESSION; GENE REPRESSION; GENOTOXICITY; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CHEMISTRY; FEMALE; METABOLISM; PHYSIOLOGY;

BREAST NEOPLASMS; CADHERINS; CHEMOKINES, CXC; E-SELECTIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; MICRORNAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, NOTCH; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 70349169955     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.06.003     Document Type: Review

References (148)

1. Hergueta-Redondo M., Palacios J., Cano A., and Moreno-Bueno G. "New" molecular taxonomy in breast cancer. Clin. Transl. Oncol. 10 (2008) 777-785
2. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., and Narod S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13 (2007) 4429-4434
3. Kurebayashi J. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer (2009) (Electronic publication ahead of print)
4. Hall J.M., Couse J.F., and Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276 (2001) 36869-36872
5. Bolton J.L., and Thatcher G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol. 21 (2008) 93-101
6. Yager J.D., and Davidson N.E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354 (2006) 270-282
7. Hopp T.A., Weiss H.L., Hilsenbeck S.G., Cui Y., Allred D.C., Horwitz K.B., and Fuqua S.A. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin. Cancer Res. 10 (2004) 2751-2760
8. Ibrahim Y.H., Byron S.A., Cui X., Lee A.V., and Yee D. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Mol. Cancer Res. 6 (2008) 1491-1498
9. Ueda Y., Wang S., Dumont N., Yi J.Y., Koh Y., and Arteaga C.L. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J. Biol. Chem. 279 (2004) 24505-24513
10. Palmieri D., Bronder J.L., Herring J.M., Yoneda T., Weil R.J., Stark A.M., Kurek R., Vega-Valle E., Feigenbaum L., Halverson D., Vortmeyer A.O., Steinberg S.M., Aldape K., and Steeg P.S. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 67 (2007) 4190-4198
11. Rakha E.A., Reis-Filho J.S., and Ellis I.O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 26 (2008) 2568-2581
12. Khalifeh I.M., Albarracin C., Diaz L.K., Symmans F.W., Edgerton M.E., Hwang R.F., and Sneige N. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am. J. Surg. Pathol. 32 (2008) 544-552
13. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., and Nielsen T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 101 (2009) 736-750
14. Yang X.R., Sherman M.E., Rimm D.L., Lissowska J., Brinton L.A., Peplonska B., Hewitt S.M., Anderson W.F., Szeszenia-Dabrowska N., Bardin-Mikolajczak A., Zatonski W., Cartun R., Mandich D., Rymkiewicz G., Ligaj M., Lukaszek S., Kordek R., and Garcia-Closas M. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 439-443
15. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet. Oncol. 8 (2007) 235-244
16. Kang S.P., Martel M., and Harris L.N. Triple negative breast cancer: current understanding of biology and treatment options. Curr. Opin. Obstet. Gynecol. 20 (2008) 40-46
17. Reis-Filho J.S., and Tutt A.N. Triple negative tumours: a critical review. Histopathology 52 (2008) 108-118
18. Vona-Davis L., Rose D.P., Hazard H., Howard-McNatt M., Adkins F., Partin J., and Hobbs G. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 3319-3324
19. Winkeljohn D.L. Triple-negative breast cancer. Clin. J. Oncol. Nurs. 12 (2008) 861-863
20. Phipps A.I., Malone K.E., Porter P.L., Daling J.R., and Li C.I. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol. Biomarkers. Prev. 17 (2008) 2078-2086
21. Trivers K.F., Lund M.J., Porter P.L., Liff J.M., Flagg E.W., Coates R.J., and Eley J.W. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control (2009) (Electronic publication ahead of print)
22. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., Harris L., Hait W., and Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24 (2006) 5652-5657
23. Atchley D.P., Albarracin C.T., Lopez A., Valero V., Amos C.I., Gonzalez-Angulo A.M., Hortobagyi G.N., and Arun B.K. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 26 (2008) 4282-4288
24. Fasano J., and Muggia F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann. Oncol. 20 (2009) 609-614
25. Young S.R., Pilarski R.T., Donenberg T., Shapiro C., Hammond L.S., Miller J., Brooks K.A., Cohen S., Tenenholz B., Desai D., Zandvakili I., Royer R., Li S., and Narod S.A. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9 (2009) 86
26. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Perou C.M., and Nielsen T.O. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14 (2008) 1368-1376
27. Diaz L.K., Cryns V.L., Symmans W.F., and Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv. Anat. Pathol. 14 (2007) 419-430
28. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green A.R., Powe D.G., El-Sayed M.E., Benhasouna A., Brunet J.S., Akslen L.A., Evans A.J., Blamey R., Reis-Filho J.S., Foulkes W.D., and Ellis I.O. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 15 (2009) 2302-2310
29. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., and van de Vijver M.J. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 9 (2007) R65
30. Tan A.R., and Swain S.M. Therapeutic strategies for triple-negative breast cancer. Cancer J. 14 (2008) 343-351
31. Mann S., Laucirica R., Carlson N., Younes P.S., Ali N., Younes A., Li Y., and Younes M. Estrogen receptor beta expression in invasive breast cancer. Hum. Pathol. 32 (2001) 113-118
32. Fox E.M., Davis R.J., and Shupnik M.A. ERbeta in breast cancer-onlooker, passive player, or active protector?. Steroids 73 (2008) 1039-1051
33. Lin C.Y., Strom A., Li Kong S., Kietz S., Thomsen J.S., Tee J.B., Vega V.B., Miller L.D., Smeds J., Bergh J., Gustafsson J.A., and Liu E.T. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res. 9 (2007) R25
34. Hartman J., Lindberg K., Morani A., Inzunza J., Strom A., and Gustafsson J.A. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 66 (2006) 11207-11213
35. Chang E.C., Frasor J., Komm B., and Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147 (2006) 4831-4842
36. Strom A., Hartman J., Foster J.S., Kietz S., Wimalasena J., and Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1566-1571
37. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., and Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64 (2004) 423-428
38. Williams C., Edvardsson K., Lewandowski S.A., Strom A., and Gustafsson J.A. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27 (2008) 1019-1032
39. Murphy L.C., and Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr. Relat. Cancer 13 (2006) 327-334
40. Skliris G.P., Lewis A., Emberley E., Peng B., Weebadda W.K., Kemp A., Davie J.R., Shiu R.P., Watson P.H., and Murphy L.C. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res. Treat 104 (2007) 75-85
41. Skliris G.P., Leygue E., Curtis-Snell L., Watson P.H., and Murphy L.C. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br. J. Cancer 95 (2006) 616-626
42. Skliris G.P., Leygue E., Watson P.H., and Murphy L.C. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J. Steroid Biochem. Mol. Biol. 109 (2008) 1-10
43. Zhang G., Liu X., Farkas A.M., Parwani A.V., Lathrop K.L., Lenzner D., Land S.R., and Srinivas H. Estrogen receptor beta functions through non-genomic mechanisms in lung cancer cells. Mol. Endocrinol. 23 (2008) 146-156
44. Gupta P.B., and Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J. Steroid Biochem. Mol. Biol. 102 (2006) 71-78
45. Gruvberger-Saal S.K., Bendahl P.O., Saal L.H., Laakso M., Hegardt C., Eden P., Peterson C., Malmstrom P., Isola J., Borg A., and Ferno M. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin. Cancer Res. 13 (2007) 1987-1994
46. Litwiniuk M.M., Roznowski K., Filas V., Godlewski D.D., Stawicka M., Kaleta R., and Breborowicz J. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer 8 (2008) 100
47. Mandusic V., Nikolic-Vukosavljevic D., Tanic N., Kanjer K., Neskovic-Konstantinovic Z., Celeketic D., and Dimitrijevic B. Expression of estrogen receptor beta wt isoform (ERbeta1) and ERbetaDelta5 splice variant mRNAs in sporadic breast cancer. J. Cancer Res. Clin. Oncol. 133 (2007) 571-579
48. Novelli F., Milella M., Melucci E., Di Benedetto A., Sperduti I., Perrone-Donnorso R., Perracchio L., Venturo I., Nistico C., Fabi A., Buglioni S., Natali P.G., and Mottolese M. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 10 (2008) R74
49. Poola I., Abraham J., Baldwin K., Saunders A., and Bhatnagar R. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization. Endocrine 27 (2005) 227-238
50. Poola I., Fuqua S.A., De Witty R.L., Abraham J., Marshallack J.J., and Liu A. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin. Cancer Res. 11 (2005) 7579-7585
51. Honma N., Horii R., Iwase T., Saji S., Younes M., Takubo K., Matsuura M., Ito Y., Akiyama F., and Sakamoto G. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol. 26 (2008) 3727-3734
52. Shaaban A.M., Green A.R., Karthik S., Alizadeh Y., Hughes T.A., Harkins L., Ellis I.O., Robertson J.F., Paish E.C., Saunders P.T., Groome N.P., and Speirs V. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res. 14 (2008) 5228-5235
53. Weiser M.J., Wu T.J., and Handa R.J. Estrogen receptor-beta agonist diarylpropionitrile: biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology 150 (2009) 1817-1825
54. Hughes Z.A., Liu F., Platt B.J., Dwyer J.M., Pulicicchio C.M., Zhang G., Schechter L.E., Rosenzweig-Lipson S., and Day M. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology 54 (2008) 1136-1142
55. Stovall D.W., and Pinkerton J.V. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women. Curr, Opin, Investig, Drugs 10 (2009) 365-371
56. Treeck O., Lattrich C., Springwald A., and Ortmann O. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res. Treat (2009)
57. Filardo E.J., Quinn J.A., and Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 73 (2008) 870-873
58. Filardo E.J., Quinn J.A., Frackelton Jr. A.R., and Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 16 (2002) 70-84
59. Filardo E.J., Quinn J.A., Bland K.I., and Frackelton Jr. A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 (2000) 1649-1660
60. Filardo E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J. Steroid. Biochem. Mol. Biol. 80 (2002) 231-238
61. Thomas P., Pang Y., Filardo E.J., and Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 (2005) 624-632
62. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., Oprea T.I., Prossnitz E.R., Musti A.M., Ando S., and Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 (2007) 1859-1866
63. Albanito L., Sisci D., Aquila S., Brunelli E., Vivacqua A., Madeo A., Lappano R., Pandey D.P., Picard D., Mauro L., Ando S., and Maggiolini M. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149 (2008) 3799-3808
64. Oliveras-Ferraros C., Vazquez-Martin A., Lopez-Bonet E., Martin-Castillo B., Del Barco S., Brunet J., and Menendez J.A. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int. J. Oncol. 33 (2008) 1165-1176
65. Ahola T.M., Purmonen S., Pennanen P., Zhuang Y.H., Tuohimaa P., and Ylikomi T. Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur. J. Biochem. 269 (2002) 2485-2490
66. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., and Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 148 (2007) 3236-3245
67. Campos S.M. Anti-epidermal growth factor receptor strategies for advanced breast cancer. Cancer Invest. 26 (2008) 757-768
68. West C.M., Joseph L., and Bhana S. Epidermal growth factor receptor-targeted therapy. Br. J. Radiol. 81 Spec No 1 (2008) S36-S44
69. Mendelsohn J. Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications. Trans. Am. Clin. Climatol. Assoc. 100 (1989) 31-38
70. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol. Immunother. 52 (2003) 342-346
71. Saba N.F., Khuri F.R., and Shin D.M. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park) 20 (2006) 153-161 discussion 162, 166, 169 passim
72. Metro G., Finocchiaro G., Toschi L., Bartolini S., Magrini E., Cancellieri A., Trisolini R., Castaldini L., Tallini G., Crino L., and Cappuzzo F. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev. Recent Clin. Trials 1 (2006) 1-13
73. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
74. Ready N. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Semin. Oncol. 32 (2005) S35-41
75. Rocha-Lima C.M., Soares H.P., Raez L.E., and Singal R. EGFR targeting of solid tumors. Cancer Control 14 (2007) 295-304
76. Kefas B., Godlewski J., Comeau L., Li Y., Abounader R., Hawkinson M., Lee J., Fine H., Chiocca E.A., Lawler S., and Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 68 (2008) 3566-3572
77. Webster R.J., Giles K.M., Price K.J., Zhang P.M., Mattick J.S., and Leedman P.J. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J. Biol. Chem. 284 (2009) 5731-5741
78. Blakeney J.S., and Fairlie D.P. Nonpeptide ligands that target peptide-activated GPCRs in inflammation. Curr. Med. Chem. 12 (2005) 3027-3042
79. Miller K.J., Murphy B.J., and Pelleymounter M.A. Central G-protein coupled receptors (GPCR)s as molecular targets for the treatment of obesity: assets, liabilities and development status. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 357-377
80. Daidone M.G., Veneroni S., Cappelletti V., Radice P., Pierotti M.A., and Younes M. Estrogen receptor-beta expression in hereditary breast cancer. J. Clin. Oncol. 20 (2002) 3752-3753 author reply 3753
81. Noruzinia M., Coupier I., and Pujol P. Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?. Cancer 104 (2005) 1567-1574
82. Fan S., Ma Y.X., Wang C., Yuan R.Q., Meng Q., Wang J.A., Erdos M., Goldberg I.D., Webb P., Kushner P.J., Pestell R.G., and Rosen E.M. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20 (2001) 77-87
83. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., Ellis N.A., Boyd J., Borgen P.I., Barakat R.R., Norton L., Castiel M., Nafa K., and Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346 (2002) 1609-1615
84. Narod S.A., Brunet J.S., Ghadirian P., Robson M., Heimdal K., Neuhausen S.L., Stoppa-Lyonnet D., Lerman C., Pasini B., de los Rios P., Weber B., and Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356 (2000) 1876-1881
85. Jin W., Chen Y., Di G.H., Miron P., Hou Y.F., Gao H., and Shao Z.M. Estrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter. J. Biol. Chem. 283 (2008) 29671-29680
86. Wu A.H., Wan P., Hankin J., Tseng C.C., Yu M.C., and Pike M.C. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 23 (2002) 1491-1496
87. Yamamoto S., Sobue T., Kobayashi M., Sasaki S., and Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J. Natl. Cancer Inst. 95 (2003) 906-913
88. Chrzan B.G., and Bradford P.G. Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines. Mol. Nutr. Food Res. 51 (2007) 171-177
89. Tominaga Y., Wang A., Wang R.H., Wang X., Cao L., and Deng C.X. Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe. Cell Death Differ. 14 (2007) 472-479
90. Privat M., Aubel C., Arnould S., Communal Y., Ferrara M., and Bignon Y.J. Breast cancer cell response to genistein is conditioned by BRCA1 mutations. Biochem. Biophys. Res. Commun. 379 (2009) 785-789
91. Shim H., Oishi S., and Fujii N. Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin. Cancer Biol. (2008)
92. Vandercappellen J., Van Damme J., and Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267 (2008) 226-244
93. Freund A., Chauveau C., Brouillet J.P., Lucas A., Lacroix M., Licznar A., Vignon F., and Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22 (2003) 256-265
94. Lin Y., Huang R., Chen L., Li S., Shi Q., Jordan C., and Huang R.P. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int. J. Cancer 109 (2004) 507-515
95. Lin Y., Wang S.M., and Huang R.P. [Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor]. Zhonghua Yi Xue Za Zhi 85 (2005) 1419-1423
96. Yao C., Lin Y., Chua M.S., Ye C.S., Bi J., Li W., Zhu Y.F., and Wang S.M. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int. J. Cancer 121 (2007) 1949-1957
97. Yao C., Lin Y., Ye C.S., Bi J., Zhu Y.F., and Wang S.M. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin. Med. J. (Engl.) 120 (2007) 1766-1772
98. Bieche I., Chavey C., Andrieu C., Busson M., Vacher S., Le Corre L., Guinebretiere J.M., Burlinchon S., Lidereau R., and Lazennec G. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr. Relat. Cancer 14 (2007) 1039-1052
99. Vazquez-Martin A., Colomer R., and Menendez J.A. Her-2/neu-induced "cytokine signature" in breast cancer. Adv. Exp. Med. Biol. 617 (2008) 311-319
100. Vazquez-Martin A., Colomer R., and Menendez J.A. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur. J. Cancer 43 (2007) 1117-1124
101. Tang Z., Yu M., Miller F., Berk R.S., Tromp G., and Kosir M.A. Increased invasion through basement membrane by CXCL7-transfected breast cells. Am. J. Surg. 196 (2008) 690-696
102. Ali S., and Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev. 26 (2007) 401-420
103. Casilli F., Bianchini A., Gloaguen I., Biordi L., Alesse E., Festuccia C., Cavalieri B., Strippoli R., Cervellera M.N., Di Bitondo R., Ferretti E., Mainiero F., Bizzarri C., Colotta F., and Bertini R. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem. Pharmacol. 69 (2005) 385-394
104. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., and Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65 (2005) 7065-7070
105. Lowery A.J., Miller N., Devaney A., McNeill R.E., Davoren P.A., Lemetre C., Benes V., Schmidt S., Blake J., Ball G., and Kerin M.J. MicroRNA signatures predict estrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 11 (2009) R27
106. Zhao J.J., Lin J., Yang H., Kong W., He L., Ma X., Coppola D., and Cheng J.Q. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283 (2008) 31079-31086
107. Adams B.D., Cowee D.M., and White B.A. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ER{alpha}) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol. Endocrinol. (2009) (Electronic publication ahead of print)
108. Adams B.D., Furneaux H., and White B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 21 (2007) 1132-1147
109. Kondo N., Toyama T., Sugiura H., Fujii Y., and Yamashita H. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 68 (2008) 5004-5008
110. Liu W.H., Yeh S.H., Lu C.C., Yu S.L., Chen H.Y., Lin C.Y., Chen D.S., and Chen P.J. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 136 (2009) 683-693
111. Miller T.E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C.L., Jacob S., and Majumder S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283 (2008) 29897-29903
112. Wickramasinghe N.S., Manavalan T.T., Dougherty S.M., Riggs K.A., Li Y., and Klinge C.M. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37 (2009) 2584-2595
113. Pandey D.P., and Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor {alpha} mRNA. Mol. Cell Biol. (2009)
114. Muttray A., Klimek L., Faas M., Schafer D., Mann W., and Konietzko J. The exposure of healthy volunteers to 200 ppm 1,1,1-trichloroethane increases the concentration of proinflammatory cytokines in nasal secretions. Int. Arch. Occup. Environ Health 72 (1999) 485-488
115. Miele L., Miao H., and Nickoloff B.J. NOTCH signaling as a novel cancer therapeutic target. Curr. Cancer Drug Targets 6 (2006) 313-323
116. Miele L. Notch signaling. Clin. Cancer Res. 12 (2006) 1074-1079
117. Miele L. Rational targeting of Notch signaling in breast cancer. Expert. Rev. Anticancer Ther. 8 (2008) 1197-1202
118. Rizzo P., Miao H., D'Souza G., Osipo C., Song L.L., Yun J., Zhao H., Mascarenhas J., Wyatt D., Antico G., Hao L., Yao K., Rajan P., Hicks C., Siziopikou K., Selvaggi S., Bashir A., Bhandari D., Marchese A., Lendahl U., Qin J.Z., Tonetti D.A., Albain K., Nickoloff B.J., and Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68 (2008) 5226-5235
119. Lee C.W., Simin K., Liu Q., Plescia J., Guha M., Khan A., Hsieh C.C., and Altieri D.C. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res. 10 (2008) R97
120. Gannett P.M., Darian E., Powell J., Johnson II E.M., Mundoma C., Greenbaum N.L., Ramsey C.M., Dalal N.S., and Budil D.E. Probing triplex formation by EPR spectroscopy using a newly synthesized spin label for oligonucleotides. Nucleic Acids Res. 30 (2002) 5328-5337
121. Lee C.W., Raskett C.M., Prudovsky I., and Altieri D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 68 (2008) 5273-5281
122. Soares R., Balogh G., Guo S., Gartner F., Russo J., and Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol. Endocrinol. 18 (2004) 2333-2343
123. Soares R., Guo S., Gartner F., Schmitt F.C., and Russo J. 17 beta-estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk. Angiogenesis 6 (2003) 271-281
124. Rizzo P., Osipo C., Foreman K., Golde T., Osborne B., and Miele L. Rational targeting of Notch signaling in cancer. Oncogene 27 (2008) 5124-5131
125. Tsai E.M., Wang S.C., Lee J.N., and Hung M.C. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 61 (2001) 8390-8392
126. Weng S.C., Kashida Y., Kulp S.K., Wang D., Brueggemeier R.W., Shapiro C.L., and Chen C.S. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol. Cancer Ther. 7 (2008) 800-808
127. Mahler-Araujo B., Savage K., Parry S., and Reis-Filho J.S. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J. Clin. Pathol. 61 (2008) 615-620
128. Habermann H., Chang W.Y., Birch L., Mehta P., and Prins G.S. Developmental exposure to estrogens alters epithelial cell adhesion and gap junction proteins in the adult rat prostate. Endocrinology 142 (2001) 359-369
129. Blaschuk O.W., Munro S.B., and Farookhi R. E-cadherin, estrogens and cancer: is there a connection?. Can. J. Oncol. 4 (1994) 291-301
130. Heijink I.H., Kies P.M., Kauffman H.F., Postma D.S., van Oosterhout A.J., and Vellenga E. Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity. J. Immunol. 178 (2007) 7678-7685
131. Nguyen M., Corless C.L., Kraling B.M., Tran C., Atha T., Bischoff J., and Barsky S.H. Vascular expression of E-selectin is increased in estrogen-receptor-negative breast cancer: a role for tumor-cell-secreted interleukin-1 alpha. Am. J. Pathol. 150 (1997) 1307-1314
132. Wang X., Chao L., Ma G., Chen L., Tian B., Zang Y., and Sun J. Increased expression of osteopontin in patients with triple-negative breast cancer. Eur. J. Clin. Invest. 38 (2008) 438-446
133. Russo J., Fernandez S.V., Russo P.A., Fernbaugh R., Sheriff F.S., Lareef H.M., Garber J., and Russo I.H. 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J. 20 (2006) 1622-1634
134. Russo J., Hasan Lareef M., Balogh G., Guo S., and Russo I.H. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid Biochem. Mol. Biol. 87 (2003) 1-25
135. Russo J., Lareef M.H., Tahin Q., Hu Y.F., Slater C., Ao X., and Russo I.H. 17Beta-estradiol is carcinogenic in human breast epithelial cells. J. Steroid Biochem. Mol. Biol. 80 (2002) 149-162
136. Chen J.Q., Russo P.A., Cooke C., Russo I.H., and Russo J. ERbeta shifts from mitochondria to nucleus during estrogen-induced neoplastic transformation of human breast epithelial cells and is involved in estrogen-induced synthesis of mitochondrial respiratory chain proteins. Biochim. Biophys. Acta 1773 (2007) 1732-1746
137. Russo J., Balogh G.A., Chen J., Fernandez S.V., Fernbaugh R., Heulings R., Mailo D.A., Moral R., Russo P.A., Sheriff F., Vanegas J.E., Wang R., and Russo I.H. The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention. Front Biosci. 11 (2006) 151-172
138. Calaf G., Tahin Q., Alvarado M.E., Estrada S., Cox T., and Russo J. Hormone receptors and cathepsin D levels in human breast epithelial cells transformed by chemical carcinogens and c-Ha-ras transfection. Breast Cancer Res. Treat 29 (1994) 169-177
139. Hu Y.F., Lau K.M., Ho S.M., and Russo J. Increased expression of estrogen receptor beta in chemically transformed human breast epithelial cells. Int. J. Oncol. 12 (1998) 1225-1228
140. Huang Y., Fernandez S.V., Goodwin S., Russo P.A., Russo I.H., Sutter T.R., and Russo J. Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. Cancer Res. 67 (2007) 11147-11157
141. Lu F., Zahid M., Saeed M., Cavalieri E.L., and Rogan E.G. Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J. Steroid Biochem. Mol. Biol. 105 (2007) 150-158
142. Saeed M., Rogan E., Fernandez S.V., Sheriff F., Russo J., and Cavalieri E. Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. Int. J. Cancer 120 (2007) 1821-1824
143. Zahid M., Gaikwad N.W., Rogan E.G., and Cavalieri E.L. Inhibition of depurinating estrogen-DNA adduct formation by natural compounds. Chem. Res. Toxicol. 20 (2007) 1947-1953
144. Zahid M., Gaikwad N.W., Ali M.F., Lu F., Saeed M., Yang L., Rogan E.G., and Cavalieri E.L. Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Free Radic. Biol. Med. 45 (2008) 136-145
145. Hu Y., Ghosh S., Amleh A., Yue W., Lu Y., Katz A., and Li R. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24 (2005) 8343-8348
146. Ghosh S., Lu Y., Katz A., Hu Y., and Li R. Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E246-E252
147. Berstein L.M. Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncol. 4 (2008) 23-39
148. Dougherty S.M., Mazhawidza W., Bohn A.R., Robinson K.A., Mattingly K.A., Blankenship K.A., Huff M.O., McGregor W.G., and Klinge C.M. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr. Relat. Cancer 13 (2006) 113-134